拉坦前列素

拉坦前列素
臨床資料
商品名（英語：Drug nomenclature）	Xalatan, others
AHFS/Drugs.com	Monograph
MedlinePlus	a697003
核准狀況	美 DailyMed: Latanoprost;
懷孕分級	澳: B3 ; ;
給藥途徑	外用眼科藥物服用（英語：Ophthalmic drug administration）
ATC碼	S01EE01 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）;
藥物動力學數據
藥物代謝	酯類水解後啟動，Β-氧化後失效
藥效起始時間（英語：Onset of action）	3–4小時
生物半衰期	17分鐘（血漿）
作用時間	≥ 24小時
排泄途徑	主要透過腎臟排泄
識別資訊
	IUPAC命名法 Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate; ;
CAS號	130209-82-4
PubChem CID	5311221;
IUPHAR/BPS	1961;
DrugBank	DB00654 ;
ChemSpider	4470740 ;
UNII	6Z5B6HVF6O;
KEGG	D00356 ;
ChEBI	CHEBI:6384 ;
ChEMBL	ChEMBL1051 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID1041057 ;
ECHA InfoCard	100.162.178
化學資訊
化學式	C26H40O5
摩爾質量	432.60 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C(OC(C)C)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCc1ccccc1;
	InChI InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1 ; Key:GGXICVAJURFBLW-CEYXHVGTSA-N ;

拉坦前列腺素（Latanoprost）是一種治療眼壓升高的藥物，是滴入眼睛的眼藥水^[5]。包括高眼壓症（英語：Ocular hypertension）和隅角開放型青光眼^[5]。藥效通常在四小時內出現，可持續長達一天^[5]。

常見副作用包括視力模糊、眼睛發紅、瘙癢和虹膜變黑^[5]。拉坦前列腺素屬於前列腺素衍生物（英語：Prostaglandin analogue）藥物家族^[5]。作用機轉是增加房水通過葡萄膜鞏膜通道流出眼睛^[6]。

拉坦前列腺素在1996年取得美國的醫療使用許可^[5]。名列世界衛生組織基本藥物標準清單^[7]。有學名藥流通於市^[8]。2017 年在美國，名列最常用處方藥第 81 名，共開出超過 900 萬張處方^[9] ^[10]。

參考文獻

^ Latanoprost 50 micrograms/ml eye drops, solution - Summary of Product Characteristics (SmPC). (emc). 1 July 2022 [1 July 2022]. （原始內容存檔於1 July 2022）.
^ Xalatan- latanoprost solution. DailyMed. 27 December 2022 [30 March 2023]. （原始內容存檔於30 March 2023）.
^ Catiolanze EPAR. European Medicines Agency (EMA). 14 September 2023 [11 December 2023]. （原始內容存檔於5 December 2023）.
^ Catiolanze Product information. Union Register of medicinal products. 16 November 2023 [11 December 2023].
^ ^5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 Latanoprost. The American Society of Health-System Pharmacists. [8 December 2016]. （原始內容存檔於28 December 2016）. "Latanoprost". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.
^ Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996, 9 (5): 363–378. PMID 8922563. doi:10.2165/00002512-199609050-00007.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 413. ISBN 9781284057560.
^ The Top 300 of 2020. ClinCalc. [11 April 2020]. （原始內容存檔於12 February 2021）.
^ Latanoprost - Drug Usage Statistics. ClinCalc. [11 April 2020]. （原始內容存檔於8 July 2020）.

[1] Latanoprost 50 micrograms/ml eye drops, solution - Summary of Product Characteristics (SmPC). (emc). 1 July 2022 [1 July 2022]. （原始內容存檔於1 July 2022）.

[Xalatan_FDA_label-2] Xalatan- latanoprost solution. DailyMed. 27 December 2022 [30 March 2023]. （原始內容存檔於30 March 2023）.

[Catiolanze_EPAR-3] Catiolanze EPAR. European Medicines Agency (EMA). 14 September 2023 [11 December 2023]. （原始內容存檔於5 December 2023）.

[Catiolanze_Product_information-4] Catiolanze Product information. Union Register of medicinal products. 16 November 2023 [11 December 2023].

[AHFS2016-5] 5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 Latanoprost. The American Society of Health-System Pharmacists. [8 December 2016]. （原始內容存檔於28 December 2016）. "Latanoprost". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.

[Pat1996-6] Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996, 9 (5): 363–378. PMID 8922563. doi:10.2165/00002512-199609050-00007.

[WHO21st-7] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Ric2015-8] Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 413. ISBN 9781284057560.

[ref-9] The Top 300 of 2020. ClinCalc. [11 April 2020]. （原始內容存檔於12 February 2021）.

[ref1-10] Latanoprost - Drug Usage Statistics. ClinCalc. [11 April 2020]. （原始內容存檔於8 July 2020）.

[3]

[4]

[1]

[2]

[5]

[6]

[7]

[8]

[9]

[10]